JP2019521161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521161A5 JP2019521161A5 JP2019502560A JP2019502560A JP2019521161A5 JP 2019521161 A5 JP2019521161 A5 JP 2019521161A5 JP 2019502560 A JP2019502560 A JP 2019502560A JP 2019502560 A JP2019502560 A JP 2019502560A JP 2019521161 A5 JP2019521161 A5 JP 2019521161A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- subject
- treatment
- medicament
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001838 canakinumab Drugs 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 16
- 208000000059 Dyspnea Diseases 0.000 claims description 14
- 206010013975 Dyspnoeas Diseases 0.000 claims description 14
- 230000004199 lung function Effects 0.000 claims description 12
- 230000005856 abnormality Effects 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 230000037081 physical activity Effects 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229960002170 azathioprine Drugs 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 235000014304 histidine Nutrition 0.000 claims description 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 3
- 229940014456 mycophenolate Drugs 0.000 claims description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 238000013125 spirometry Methods 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365017P | 2016-07-21 | 2016-07-21 | |
| US62/365,017 | 2016-07-21 | ||
| PCT/IB2017/054360 WO2018015897A1 (en) | 2016-07-21 | 2017-07-19 | Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521161A JP2019521161A (ja) | 2019-07-25 |
| JP2019521161A5 true JP2019521161A5 (cg-RX-API-DMAC10.html) | 2020-08-27 |
Family
ID=59683618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502560A Pending JP2019521161A (ja) | 2016-07-21 | 2017-07-19 | 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210292404A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3487584A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2019521161A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20190032436A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017298656A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3031346A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018015897A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202400340D0 (en) | 2024-01-10 | 2024-02-21 | Wotherspoon Hugh Robert | IL-1B binding antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US10000565B2 (en) * | 2012-11-16 | 2018-06-19 | Novartis Ag | Use of IL-1 β binding antibodies for treating peripheral arterial disease |
-
2017
- 2017-07-19 EP EP17755243.7A patent/EP3487584A1/en not_active Withdrawn
- 2017-07-19 AU AU2017298656A patent/AU2017298656A1/en not_active Abandoned
- 2017-07-19 KR KR1020197004681A patent/KR20190032436A/ko not_active Ceased
- 2017-07-19 JP JP2019502560A patent/JP2019521161A/ja active Pending
- 2017-07-19 US US16/319,630 patent/US20210292404A1/en not_active Abandoned
- 2017-07-19 CA CA3031346A patent/CA3031346A1/en not_active Abandoned
- 2017-07-19 WO PCT/IB2017/054360 patent/WO2018015897A1/en not_active Ceased
-
2020
- 2020-07-20 AU AU2020207771A patent/AU2020207771A1/en not_active Abandoned
-
2022
- 2022-02-18 US US17/675,488 patent/US20220177570A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Noord et al. | The efficacy of tiotropium administered via Respimat® Soft Mist™ Inhaler or HandiHaler® in COPD patients | |
| Moore et al. | Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate | |
| US6903100B2 (en) | Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JP2017510607A5 (cg-RX-API-DMAC10.html) | ||
| JP2020515530A5 (cg-RX-API-DMAC10.html) | ||
| JP2011190199A (ja) | 関節リウマチ薬 | |
| JP2018531605A5 (cg-RX-API-DMAC10.html) | ||
| Waheed et al. | Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major | |
| CN111107845A (zh) | 西尼莫德的给药方案 | |
| JP2019506397A5 (cg-RX-API-DMAC10.html) | ||
| Waxman et al. | Limited benefit of atropine as premedication for colonoscopy | |
| Klein et al. | A double‐blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension | |
| Akbulut et al. | Propofol with and without midazolam for diagnostic upper gastrointestinal endoscopies in children | |
| Buzzigoli et al. | Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobulin | |
| Verrill et al. | Vasovagal faint in the supine position | |
| Nikolaizik et al. | A Pilot Study to Compare Tobramycin 80 mg Injectable Preparation wth 300 mg Solution for Inhalation in Cystic Fibrosis Patients | |
| EP4615451A1 (en) | Uses of bupivacaine multivesicular liposomes as stellate ganglion block for treating anxiety disorders and traumatic brain injury | |
| Clozel et al. | Hemodynamic effects of intravenous diltiazem in hypoxic pulmonary hypertension | |
| Chen et al. | A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension | |
| Wang et al. | Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease | |
| JP6420923B1 (ja) | 医薬 | |
| Kopecky et al. | Enalaprilat-enhanced renography in a rat model of renovascular hypertension | |
| Duarte et al. | Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease? | |
| Kobayashi et al. | Effect of long-term administration of buflomedil on regional cerebral blood flow in chronic cerebral infarction |